161 related articles for article (PubMed ID: 29264528)
41. Hormonal contraception and venous thromboembolism.
Lidegaard Ø; Milsom I; Geirsson RT; Skjeldestad FE
Acta Obstet Gynecol Scand; 2012 Jul; 91(7):769-78. PubMed ID: 22568831
[TBL] [Abstract][Full Text] [Related]
42. Contraception-related venous thromboembolism in adolescents.
O'Brien SH
Semin Thromb Hemost; 2014 Feb; 40(1):66-71. PubMed ID: 24356931
[TBL] [Abstract][Full Text] [Related]
43. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users.
Sidney S; Cheetham TC; Connell FA; Ouellet-Hellstrom R; Graham DJ; Davis D; Sorel M; Quesenberry CP; Cooper WO
Contraception; 2013 Jan; 87(1):93-100. PubMed ID: 23083525
[TBL] [Abstract][Full Text] [Related]
44. Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?
Han L; Jensen JT
Obstet Gynecol Clin North Am; 2015 Dec; 42(4):683-98. PubMed ID: 26598309
[TBL] [Abstract][Full Text] [Related]
45. Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception.
Cosmi B; Legnani C; Bernardi F; Coccheri S; Palareti G
Arch Intern Med; 2003 May; 163(9):1105-9. PubMed ID: 12742811
[TBL] [Abstract][Full Text] [Related]
46. Epidemiology of hormonal contraceptives-related venous thromboembolism.
Hugon-Rodin J; Gompel A; Plu-Bureau G
Eur J Endocrinol; 2014 Dec; 171(6):R221-30. PubMed ID: 25012200
[TBL] [Abstract][Full Text] [Related]
47. Self-reported family history in estimating the risk of hormone, surgery and cast related VTE in women.
Sonnevi K; Bergendal A; Adami J; Lärfars G; Kieler H
Thromb Res; 2013 Aug; 132(2):164-9. PubMed ID: 23800637
[TBL] [Abstract][Full Text] [Related]
48. Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology.
Gourdy P; Bachelot A; Catteau-Jonard S; Chabbert-Buffet N; Christin-Maître S; Conard J; Fredenrich A; Gompel A; Lamiche-Lorenzini F; Moreau C; Plu-Bureau G; Vambergue A; Vergès B; Kerlan V
Ann Endocrinol (Paris); 2012 Nov; 73(5):469-87. PubMed ID: 23078975
[TBL] [Abstract][Full Text] [Related]
49. Smoking and use of oral contraceptives: impact on thrombotic diseases.
Lidegaard O
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S357-63. PubMed ID: 10368521
[TBL] [Abstract][Full Text] [Related]
50. Contraception-related venous thromboembolism in a pediatric institution.
Pillai P; Bonny AE; O'Brien SH
J Pediatr Adolesc Gynecol; 2013 Jun; 26(3):186-8. PubMed ID: 23566795
[TBL] [Abstract][Full Text] [Related]
51. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
52. Impact of UK Medical Eligibility Criteria implementation on prescribing of combined hormonal contraceptives.
Briggs PE; Praet CA; Humphreys SC; Zhao C
J Fam Plann Reprod Health Care; 2013 Jul; 39(3):190-6. PubMed ID: 23299629
[TBL] [Abstract][Full Text] [Related]
53. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.
Sehovic N; Smith KP
Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756
[TBL] [Abstract][Full Text] [Related]
54. Decision support systems in clinical practice: The case of venous thromboembolism prevention.
Nazarenko GI; Kleymenova EB; Payushik SA; Otdelenov VA; Sychev DA; Yashina LP
Int J Risk Saf Med; 2015; 27 Suppl 1():S104-5. PubMed ID: 26639683
[TBL] [Abstract][Full Text] [Related]
55. Canadian Contraception Consensus (Part 2 of 4).
Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
[TBL] [Abstract][Full Text] [Related]
56. Canadian Contraception Consensus (Part 1 of 4).
Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N;
J Obstet Gynaecol Can; 2015 Oct; 37(10):936-42. PubMed ID: 26606712
[TBL] [Abstract][Full Text] [Related]
57. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties.
Koster T; Small RA; Rosendaal FR; Helmerhorst FM
J Intern Med; 1995 Jul; 238(1):31-7. PubMed ID: 7608644
[TBL] [Abstract][Full Text] [Related]
58. Searching for Information on the Risks of Combined Hormonal Contraceptives on the Internet: A Qualitative Study Across Six European Countries.
Gomes Alves P; Petersen I; Stevenson F
J Med Internet Res; 2019 Mar; 21(3):e10810. PubMed ID: 30882358
[TBL] [Abstract][Full Text] [Related]
59. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10.
Lidegaard O; Nielsen LH; Skovlund CW; Løkkegaard E
BMJ; 2012 May; 344():e2990. PubMed ID: 22577198
[TBL] [Abstract][Full Text] [Related]
60. [Venous thrombo-embolism during immune-mediated thrombotic thrombocytopenic purpura is prevalent in patients with a prolonged treatment with therapeutic plasma exchange].
Benhamou Y; Sauvètre G; Grangé S; Veyradier A; Coppo P
Rev Med Interne; 2020 Dec; 41(12):809-813. PubMed ID: 32727695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
